| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| LEVONORDEFRIN | Identification/B: | USP43–NF38 | 2611 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change Ultraviolet Absorption <197U>— to: Spectroscopic Identification Tests <197>, Ultraviolet-Visible Spectroscopy: 197U |
| LEUCOVORIN CALCIUM FOR INJECTION | ASSAY/Procedure/Chromatographic system | USP43–NF38 | 2569 | 24-Apr-2020 | 1-May-2020 | NA | NA | Delete Run time: 2 times the retention time of the leucovorin peak |
| EPINEPHRINE | ADDITIONAL REQUIREMENTS | USP43–NF38 | Online | 24-Apr-2020 | 1-May-2020 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. In USP Reference Standards <11>: Add USP Racepinephrine Hydrochloride RS |
| EPINEPHRINE | IMPURITIES/Enantiomeric Purity | USP43–NF38 | Online | 24-Apr-2020 | 1-May-2020 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. In System suitability solution: Change 0.03 mg/mL of in Mobile phase to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in Mobile phase |
| EPINEPHRINE | IMPURITIES/Organic Impurities | USP43–NF38 | 1645 | 24-Apr-2020 | 1-May-2020 | NA | NA | In the third calculation in the Analysis: Change CU = concentration of Epinephrine in the Sample solution (mg/mL) to: CU = concentration of Epinephrine in the Sample solution (µg/mL) |
| DIHYDROERGOTAMINE MESYLATE | Assay | USP43–NF38 | 1388 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change Diluent 1—Prepare a solution of 0.1 mL of phosphoric acid in 1000 mL of water. Diluent 2—Prepare a mixture of Diluent 1 and acetonitrile (60:40). to: Diluent 1—Prepare a solution of 0.1 mL of phosphoric acid in 1000 mL… Read More |
| DEXAMETHASONE ACETATE | Chromatographic purity | USP43–NF38 | 1290 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change Format buffer to: Formate buffer |
| DEMECLOCYCLINE HYDROCHLORIDE | SPECIFIC TESTS/Loss on Drying | USP43–NF38 | 1248 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Analysis: Change Dry the Sample at 60° for 3 h. to: Dry the Sample in a capillary-stoppered bottle in vacuum at 60° for 3 h. |
| DAPSONE TABLETS | IDENTIFICATION/B. | USP43–NF38 | 1241 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change Ultraviolet Absorption <197U> to: Spectroscopic Identification Tests <197>, Ultraviolet-Visible Spectroscopy: 197U |
| REPOSITORY CORTICOTROPIN INJECTION | ADDITIONAL REQUIREMENTS | USP43–NF38 | 1174 | 24-Apr-2020 | 1-May-2020 | NA | NA | In USP Reference Standards <11>: Add USP Ascorbic Acid RS |
| CARISOPRODOL | IMPURITIES/Organic Impurities | USP43–NF38 | 776 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Table 2: Change Carisoprdol related compound Aa to: Carisoprodol related compound Aa |
| BUDESONIDE | IMPURITIES/Organic Impurities | USP43–NF38 | 604 | 24-Apr-2020 | 1-May-2020 | NA | NA | In footnote k in Table 2: Change 16α,17-[Butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4-diene-3,20-dione-21-acetate. to: 16α,17-[Butylidenebis(oxy)]-11β-hydroxypregna-1,4-diene-3,20-dione-21-yl acetate. |
| CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 915 | 24-Apr-2020 | 1-May-2020 | NA | NA | In USP Cetirizine Related Compound A RS: Change 506.98 to: 506.97 |
| ALOSETRON HYDROCHLORIDE | IMPURITIES/Organic Impurities | USP43–NF38 | 141 | 24-Apr-2020 | 1-May-2020 | NA | NA | In System suitability/Suitability requirements/Resolution: Change NLT 7 to: NLT 3 |
| ITRACONAZOLE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 1 | Revision Bulletin (Official August 01, 2019) | Online | 27-Mar-2020 | 1-Apr-2020 | NA | NA | In System suitability/Suitability requirements/Relative standard deviation: Change NMT 2.0% for 5 replicate injections to: NMT 2.0% for 5 replicates |
| ANTITHROMBIN III HUMAN | ADDITIONAL REQUIREMENTS | USP42–NF37 | 350 | 27-Mar-2020 | 1-Apr-2020 | NA | NA | In Labeling: Change USP Antithrombin III Units. to: Antithrombin III IU. |
| ANTITHROMBIN III HUMAN | SPECIFIC TESTS | USP42–NF37 | 350 | 27-Mar-2020 | 1-Apr-2020 | NA | NA | In Pyrogen Test <151>: Change USP Antithrombin III Units to: Antithrombin III IU |
| CALCIUM ACETATE CAPSULES | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official January 01, 2020) | Online | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Test 1/Analysis: Change dissolved at time point (i): Resulti = (rU/rS) × CS × V × D × (1/L) × 100 to: dissolved: … Read More |
| LITHIUM CARBONATE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | USP42–NF37 | 2598 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Analysis: Change V = volume of Medium, 900 mL to: V = volume of Medium, 800 mL |
| FLUNIXIN MEGLUMINE INJECTION | IMPURITIES/Organic Impurities | USP42–NF37 | 1890 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Sensitivity solution: Change in Diluent from the Standard solution to: in Diluent |
| DICLOXACILLIN SODIUM CAPSULES | PERFORMANCE TESTS | USP42–NF37 | 1330 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Dissolution <711>: Change Sample solution: Sample per the chapter. Dilute with Medium to a concentration that is similar to the Standard solution. Tolerances: NLT 75% (Q) of the labeled amount of… Read More |
| MEROPENEM FOR INJECTION | ASSAY/Procedure | Second Supplement to USP42–NF37 | 9216 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | In Mobile phase: Change Solution A to: Buffer |
| ALFADEX | CHEMICAL INFORMATION | USP42–NF37 | 5561 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | Change 972.84 to: 972.85 |
| POLYETHYLENE GLYCOL | CHEMICAL INFORMATION | USP42–NF37 | 5882 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction |
| <121> INSULIN ASSAYS | ASSAY/Rabbit Blood Sugar Method—Quantitative | Revision Bulletin (Official May 01, 2019) | Online | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard stock solution: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In Sample stock solution: Change of USP Insulin RS of the appropriate species.… Read More |
| <857> ULTRAVIOLET-VISIBLE SPECTROSCOPY | QUALIFICATION OF UV-VIS SPECTROMETERS | Second Supplement to USP42–NF37 | 9570 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In all instances in Table 4: Change < to: ≤ AND In Control of Photometric Response/Acidic Nicotinic Acid Solutions in 0.1 N Hydrochloric Acid/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy… Read More |
| CUPRIC CHLORIDE | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6092 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | Change [7447-39-4]. to: [10125-13-0]. |
| CYPROHEPTADINE HYDROCHLORIDE ORAL SOLUTION | IMPURITIES/Organic Impurities | USP42–NF37 | 1195 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard solution: Change in Solution B to: in Diluent |
| <1227> VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES | VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS | Second Supplement to USP42–NF37 | 9616 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In paragraph 1 in Recovery on Agar Medium: Change If it is necessary to solubilize the test stample, to: If it is necessary to solubilize the test sample, |
| MEFENAMIC ACID CAPSULES | PERFORMANCE TESTS/Dissolution <711> | USP42–NF37 | 2711 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Solution A, Mobile phase, Standard solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay, making any necessary volumetric adjustments. to: … Read More |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS | IMPURITIES/Organic Impurities | Second Supplement to USP42–NF37 | 9101 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Table 4, Footnote h: Change 0.47, to: 0.45, |
| SIMVASTATIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP42–NF37 | 4009 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Standard solution: Change USP Simvastatin RS in Medium to: USP Simvastatin RS in Medium. Transfer a portion of the solution to a centrifuge tube containing about 10 mg of Prewashed manganese dioxide per milliliter of… Read More |
| ZIPRASIDONE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 3/Tier 2 | Revision Bulletin (Official October 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Buffer: Change 6.8 g/L g to: 6.8 g/L AND In Standard stock solution 2: Change Standard stock solution to: Standard stock solution 1 |
| 2,5-DIHYDROXYBENZOIC ACID | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6097 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change [303-07-1]. to: [490-79-9]. |
| 0.1 N POTASSIUM HYDROXIDE VS | REAGENTS AND REFERENCE TABLES/Solutions | USP42–NF37 | 6185 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Standardization: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced. to: Standardization: Add 2 drops of phenolphthalein TS… Read More |
| 25% TETRABUTYLAMMONIUM HYDROXIDE TS | REAGENTS AND REFERENCE TABLES/Solutions | Second Supplement to USP42–NF37 | 9336 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Transfer about 34.82 g to: Transfer about 77.1 g |
| <1430> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—GENERAL | 1. OVERVIEW: GENERAL CHAPTERS BASED ON SCATTERING PHENOMENA | Second Supplement to USP42–NF37 | 9634 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Row 6 of Column 4 in Table 1: Change Also properties of condensated phrases to: Also properties of condensated phases |
| <1430.5> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING | 6. EXPERIMENTAL CONSIDERATIONS | Second Supplement to USP42–NF37 | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In 6.2 Resolution/6.2.1 Size resolution: Change qmin < π/dmax π/dmax to: qmin < π/dmax |
| ROPINIROLE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official July 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Test 2 and Test 3 in Analysis: Change Result1 = C1 × (1/L) × (Mr1/Mr2) × 100 to: Result1 = C1 × V × (1/L… Read More |
| SODIUM BICARBONATE | IMPURITIES/Carbonate/Analysis | USP42–NF37 | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Remove the external reference to a reagent in Sodium Bicarbonate |
| <1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE | INTRODUCTION | USP42–NF37 | 8021 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU |
| GADOTERIDOL | Limit of gadoteridol related compound A | USP42–NF37 | 2020 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Chromatographic system: Change packing L21 to: packing L47 |
| HYPROMELLOSE ACETATE SUCCINATE | ASSAY | USP42–NF37 | 5772 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis: Change Result = (rUM/rSM) × (CS/CU) × (Mr1/Mr2) to: Result… Read More |
| <55> BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS | D-VALUE DETERMINATION | USP42–NF37 | 6385 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the third paragraph in Procedure: Change stated spore filter to: stated spore titer |
| <1228.4> DEPYROGENATION BY RINSING | ROUTINE PROCESS CONTROL | USP42–NF37 | 8067 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the first paragraph: Change WFI to: Water for Injection |
| <2022> MICROBIOLOGICAL PROCEDURES FOR ABSENCE OF SPECIFIED MICROORGANISMS—NUTRITIONAL AND DIETARY SUPPLEMENTS | BUFFER AND MEDIA/Media | USP42–NF37 | 8514 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Row 5 of Column 2 for L-Cystine in Fluid Selenite–Cystine Medium: Change 10.0 g to: 10.0 mg |
| <1229.2> STEAM STERILIZATION OF AQUEOUS LIQUIDS | BIOBURDEN/BIOLOGICAL INDICATOR METHOD/Routine Process Control | USP42–NF37 | 8082 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the first paragraph: Change calibrartion to: calibration |
| ANAGRELIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Analysis | USP42–NF37 | 329 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change Result = (rU/rS) x (CS/CU) x (Mr1/Mr2) x (V/L) x 100 to: Result = (rU/rS) x… Read More |
| DESFLURANE | CHEMICAL INFORMATION | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether to: (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane. |
| DESFLURANE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Desflurane Related Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane. |